Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07422480 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
A Phase 3 study of Myelodysplastic Syndrome and Anemia, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07422480: Recruiting Phase 3 study of Myelodysplastic Syndrome and Anemia, sponsored by Takeda.
NCT07422480 is a Phase 3 study of Myelodysplastic Syndrome and Anemia that is actively recruiting participants, run by Takeda. The registered enrollment target is 300 participants, above the 205-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07422480, a Phase 3 study of Myelodysplastic Syndrome and Anemia, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion compared with epoetin alfa, the RBC transfusion burden and quality of life compared with epoetin alfa. The study also aims to find out the extent of the immune response to elritercept. The study will also check on the medical problems (safety) of elritercept.
Primary Outcome
RBC-TI is defined as no red blood cell (RBC) transfusions administered for the specified time period during study treatment.
Conditions Studied
Interventions
- DRUG Elritercept
- DRUG Epoetin Alfa
Study Locations (20)
Texas
- World Research Link - Baytown
- The Center for Cancer and Blood Disorders - Fort Worth
- The University of Texas-MD Anderson Cancer Center - Leukemia Center - Houston
Tennessee
- Tennessee Oncology, PLLC - Nashville
- Vanderbilt University Medical Center - Nashville
California
- Hematology-Oncology Medical Group of Orange County, Inc - Orange - 1010 W. La Veta Avenue - Orange
Florida
- BRCR Medical Center Inc - Tamarac
Georgia
- Emory University - Atlanta
Illinois
- Orchard Healthcare Research Inc. (OHR) - Skokie - Skokie
Kentucky
- Norton Cancer Institute - Louisville
Missouri
- American Oncology Partners P.A. MidAmerica Cancer Care - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2033-10-01 |
| Phase | Phase 3 |
What NCT07422480 shows while recruiting
NCT07422480 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 205-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (46% higher).
The record links to 2 conditions, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Elritercept is the first listed.
NCT07422480 names 20 study sites across 17 states, led by Texas, Tennessee, California.
Frequently Asked Questions
What is clinical trial NCT07422480 about?
NCT07422480 is a clinical study titled "A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions". The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion ...
What is the current status of trial NCT07422480?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-04-01. Estimated completion is 2033-10-01.
What conditions does trial NCT07422480 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome, Anemia.
What interventions are being tested in trial NCT07422480?
The interventions under investigation include: Elritercept (DRUG), Epoetin Alfa (DRUG).
Who is sponsoring clinical trial NCT07422480?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07422480 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07422480's enrollment target sits among peer trials
300 11th of 134 higher than 124 of 134 other Myelodysplastic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 3
-
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
COMPLETED · Phase 3
-
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI